Navigation Links
Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
Date:3/13/2008

ch forward-looking statements or information. Such factors include, among others, the availability of clinical trial materials; the possibility that we will not be able to recruit patients for our planned trials in a timely manner; our need for capital, risks associated with requirements for approvals by government agencies such as the FDA before products can be tested in clinical trials; the possibility that such government agency approvals will not be obtained in a timely manner or at all or will be conditioned in a manner that would impair our ability to advance development; risks associated with the requirement that a drug be found safe and effective after extensive clinical trials: our dependence on suppliers, collaborative partners and other third parties and the prospects and timing for negotiating supply agreements, corporate collaborations or licensing arrangements; our ability to attract and retain key personnel; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at http://www.sedar.com.

Assumptions underlying our expectations regarding forward-looking statements or information contained in this press release include, among others, that we will raise enough capital, on reasonable terms and in a timely manner; that we will retain our key personnel; that we will obtain the necessary regulatory approvals related to HspE7 + Poly-ICLC in a timely manner; that enough HspE7 and Poly-ICLC will be available to conduct our planned trials; that we will obtain timely approval from additional IRBs; that the results from additional preclinical and clinical work, if any, will be consistent with the results we have already obtained; that a sufficient number of patients will be available to conduct our planned trials; and that sufficient data will be generated to support our BLA. In the event that any of these assumptions prove to be incorrect, or in the event t
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
2. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
3. Nventa updates progress of cervical dysplasia trial with new HspE7
4. Nventas CEO to present at two upcoming investor conferences
5. Nventa announces publication of HspE7 data
6. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
7. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
8. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals Announces Additions to Management Team
11. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... According to a new market research ... - Global Trends & Forecasts up till 2017”, hydraulic ... 2011. This value is expected to increase from $40 ... 10% CAGR during the same period. North America is ... in terms of hydraulic horse power supplied by the ...
(Date:10/18/2014)... (PRWEB) October 18, 2014 The ... Stress, Holter Monitor), by End-user (Hospitals, Home/Ambulatory, Research ... (Single, 3-6, 12) -Global Forecast to 2020” provides ... challenges, opportunities, current market trends, and strategies impacting ... estimates and forecasts of the revenue and share ...
(Date:10/17/2014)... through the looking-glass to Wonderland, mirrors in the real ... including a new class of mirror that works like ... Optical Society,s (OSA) new high-impact journal Optica ... a new type of mirror that forgoes a familiar ... using an unusual magnetic property of a non-metallic metamaterial. ...
(Date:10/17/2014)... 17, 2014 For the seventh ... as published in today’s print issue of Science ... Top Employers Survey polled employees in the biotechnology, ... best employers. Rankings were determined based on ... rate their companies on 23 characteristics, including financial ...
Breaking Biology Technology:Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 2Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 3Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 4The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 2The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 3The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 4The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 5Magnetic mirrors enable new technologies by reflecting light in uncanny ways 2Magnetic mirrors enable new technologies by reflecting light in uncanny ways 3Magnetic mirrors enable new technologies by reflecting light in uncanny ways 4DuPont Named Top Employer by Science Magazine 2DuPont Named Top Employer by Science Magazine 3
... Telik, Inc. (Nasdaq: TELK ) announced ... focus on its most advanced preclinical and clinical ... the company to continue the development of TELINTRA(R) ... prodrug cytotoxic, TLK58747, and dual Aurora-VEGFR kinase inhibitor, ...
... Ltd. (Nasdaq: XTLB ; TASE: XTL) today ... been appointed to XTL,s Board of,Directors, effective today. ... of Co-Chief Executive Officer, with no remuneration, to assist ... Ron Bentsur, Co-Chief Executive Officer of XTL, ...
... China, Feb. 11 /PRNewswire-Asia/ -- Sundia MediTech Company, ... announced,today that the company was selected in Deloitte ... publishes Technology Fast 500 list every,year for regions ... to recognize,in each region the technology companies that ...
Cached Biology Technology:Telik Implements Reorganization to Focus Resources Toward Drug Development Pipeline 2XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors 2XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors 3
(Date:10/14/2014)... A new study published in Cancer Research ... liver and colon cancers—can promote the development of skin ... proliferation and survival of sun-damaged skin cells. , Previously ... seven proteins called sirtuins that help regulate genomic stability ... aging. SIRT6 helps repair DNA damage, which can lead ...
(Date:10/14/2014)... Sinai-led research team has discovered a new kind of stem ... cell that lines liver blood vessels, according to a study ... The existence of such a cell type contradicts current theory ... and may hold clues to origins of, and future treatment ... a single cell into a complex being made up of ...
(Date:10/14/2014)... of researchers, led by the Chinese Academy of Agricultural ... Genetics a brief genomic history of tomato breeding, ... plant. , The C.M. Rick Tomato Genetics Resource Center ... study by providing seed of both cultivated tomato varieties ... on the first tomato genome sequence completed just two ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3
... have been tracking the evolution of Drosophila subobscura , ... since 1976. They are focusing on a specific type of ... compared how the flies, genomes change from spring to summer, ... In pre-2011 studies of one of D. subobscura ...
... A recent article in the New England Journal ... blood cancer called atypical chronic neutrophilic leukemia (CNL) that ... the disease. The mutation also serves as an Achilles ... Center to prescribe a never-before-used, targeted treatment. The first ...
... State University researcher is the first to show that the ... for a U.S. city. Jeremy Diem, an associate professor ... nine weather stations in the Atlanta metropolitan area from 1948 ... late 1970s as pollution decreased following passage of the Clean ...
Cached Biology News:First evidence that the genome can adapt to temperature changes 2New disease-to-drug genetic matching puts snowboarder back on slopes 2New disease-to-drug genetic matching puts snowboarder back on slopes 3
... RNA OligoMix or individual RNA sequences from high ... custom small RNAs from LC Sciences. These products ... to millions) of DESIGNED sequences delivered in a ... each containing a single verified RNA sequence. This ...
... automated bioresearch: Developed for a wide ... on decades of experience in Luminescence ... bioresearch • Holographic gratings for reduced ... ease-of-use • Pulsed Xenon lamp reduces ...
... Acuity is the complete enterprise microarray informatics ... data analysis. Buy Acuity once and use it ... Analysis Tools for Quality Acuity has all ... most from your data, from quality control statistics ...
... precise 96 and 384-well transfers in a ... 200ul disposable tips, the 96 channel parallel ... across a volume range from 1-200uls. The ... that enable indexing into 384 well plates, ...
Biology Products: